Palm Therapeutics
Peter Chu is a scientist-turned-entrepreneur, biotech executive and investor who has spent the last 15+ years on both the research and executive management side of small, medium and large biotech companies. He was the founding CEO of Eclipse Therapeutics, a Biogen Idec (NASDAQ:BIIB) spinout that was acquired by Bionomics Ltd (BNO:ASX), where he led development of the cancer stem cell antibody BNC101 from conception through to human clinical trials in colon cancer. He is a board director at Echo Laboratories.
This person is not in the org chart
This person is not in any teams
This person is not in any offices